Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

There are many reasons you may want to consider reducing your sodium intake, especially if you have high blood pressure. And it probably comes as no surprise that fast-food menus can be difficult to ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

DEAR DR. ROACH: My mother’s blood test has a sodium level of 130 mEq/L. She is not on diuretics, and she does not have heart or kidney problems. She is on thyroid medication and omeprazole.

Dear Dr. Roach: My mother’s blood test has a sodium level of 130 mEq/L. She is not on diuretics, and she does not have heart or kidney problems. She is on thyroid medication and omeprazole.

Figure 2. Photographs of the tubular seep carbonate SQW-65. The dashed blue line represents the dividing line between zones B and C. The dashed yellow line represents the dividing line between zones B ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.